Cargando…
Sm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons
Schistosomiasis is a neglected parasitic disease of major public health concern as it affects over 250 million people in developing countries. Currently there is no licensed vaccine available against schistosomiasis. The Schistosoma mansoni calpain protein, Sm-p80, is a leading vaccine candidate now...
Autores principales: | Rojo, Juan U., Melkus, Michael W., Kottapalli, Kameswara Rao, Okiya, Oscar E., Sudduth, Justin, Zhang, Weidong, Molehin, Adebayo J., Carter, Darrick, Siddiqui, Afzal A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5305113/ https://www.ncbi.nlm.nih.gov/pubmed/28192534 http://dx.doi.org/10.1371/journal.pone.0171677 |
Ejemplares similares
-
Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer Protection in vivo and in vitro From Schistosoma mansoni and Identification of Putative Correlative Markers of Protection
por: Zhang, Weidong, et al.
Publicado: (2020) -
Process Development of Sj-p80: A Low-Cost Transmission-Blocking Veterinary Vaccine for Asiatic Schistosomiasis
por: Molehin, Adebayo J., et al.
Publicado: (2021) -
Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models
por: Zhang, Weidong, et al.
Publicado: (2018) -
Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment
por: Melkus, Michael W., et al.
Publicado: (2020) -
Schistosomiasis vaccine development: update on human clinical trials
por: Molehin, Adebayo J.
Publicado: (2020)